As of Wednesday, December 31, Xeris Biopharma Holdings, Inc.’s XERS share price has surged by 8.66%, which has investors questioning if this is right time to sell.
Zacks Investment Research on MSN
KRMD submits 510(k) to use FreedomEDGE system with oncology biologic
KORU Medical Systems, Inc.KRMD recently announced that it has submitted a 510(k) premarket notification for FDA clearance to ...
The Wegovy pill is expected to hit the market in January, joining injectable GLP-1 drugs that have transformed obesity treatment. One form you swallow, the other you inject. What else is different?
Delcath Systems, Inc. , ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results ...
In the vast landscape of biotechnology and endocrinology, few compounds have a backstory as serendipitous or a mechanism as ...
This is branded content for Zoetis As the Australian beef industry shifts towards more feedlotting, ensuring young ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback